To determine the optimal doses of the antiepidermal growth factor receptor ( anti-EGFR ) monoclonal antibody cetuximab and the EGFR tyrosine kinase inhibitor gefitinib when administered as a combination for patients with advanced/metastatic non-small cell lung cancer ( NSCLC ) previously treated with platinum-based chemotherapy .
